{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-160348","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2023-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.692782+00:00","generated_at":"2026-06-14T07:29:52.901827+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Taysha doses first patient with TSHA-102 in Phase 1/2 REVEAL trial for Rett syndrome","bullets":["First adult patient received TSHA-102, an AAV9 gene therapy using miRARE technology to regulate MECP2.","Phase 1/2 REVEAL trial: open-label, dose-escalation (5x10^14 vg then 1x10^15 vg) and dose-expansion in adult females.","Initial safety data from first patient expected at R&D Day on June 28, 2023.","Study conducted at CHU Sainte-Justine in Montreal, Canada; independent data monitoring committee will review safety at ~6 weeks.","First time a gene therapy is evaluated clinically for Rett syndrome, per Taysha management."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-160348","json":"https://secwatch.observer/filing/0001193125-23-160348.json","markdown":"https://secwatch.observer/filing/0001193125-23-160348.md","text":"https://secwatch.observer/filing/0001193125-23-160348.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523160348/0001193125-23-160348-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523160348/d513071d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T07:29:52.901827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}